Category Archives: Government

The worldwide battle over health spending, especially high drug prices, and whether it’s actually worth it. The view from afar.

Commentary: Steve Walker The “Medicare for All” plan embraced by leading 2020 Democrats looks more lavish than what other advanced countries offer, compounding the cost but also potentially broadening its… Read more »

Medical stocks resemble Mr. Toad’s Wild Ride with brave investors tightening their seat belts and neck braces for more uncertainty, price fluctuation.

Health-sector stocks were whipsawed upward, downward, backward and forward last week, rekindling memories of the Yardbirds’ hit song in the 60’s with a similar name. Still, when the dust settled,… Read more »

Seven health-sector IPOs do the limbo and raise $499M, seconds before market falls off a cliff.

Trade war fears are crushing stocks, and the their swan dive onto the rocks could keep going if Presidents Trump and China’s Xi Jinping keep tossing tariff grenades at each… Read more »

Healthcare IPOs still on a tear as pricings and registrations keep Wall Street, SEC on their toes.

Despite President Trump’s threatening trade Tweets to China and the resulting drag on stocks, only the health sector came out ahead on Monday (May 6, 2019), and the IPO action… Read more »

IPOs are back in business; well, unless and until there’s another government shutdown.

IPOs are back in the race for torrents of cash. The government is fully funded until February 15, which means a wave of IPOs should begin launching today (Feb. 4)…. Read more »

Health-sector investors hold breath as 2018 mercifully comes to a close; but what does 2019 portend? Anyone else cringe at prime-number years?

As investors stagger toward the New Year, adjusting their neck braces for one final lap of trading on December 31, there’s one big consolation for the recent, massive, daily twists… Read more »

PART TWO: The future of Russian pharma. Why does China (among so many others) surpass Russia when it comes to pharma/biotech innovation?

In examining why Russia is behind its neighbor China in pharma and biotech innovation, one must keep in mind that Chinese medicine is a style of traditional treatment built on a foundation… Read more »